Literature DB >> 28741075

Brain relaxometry after macrocyclic Gd-based contrast agent.

Andreas Müller1, Alina Jurcoane1, Burkhard Mädler2, Philip Ditter1, Hans Schild1, Elke Hattingen3.   

Abstract

PURPOSE: To assess if ratios of T1-weighted (T1w) signal intensity (SI) and quantitative T1 relaxometry (qT1) change on serial administration of macrocyclic gadobutrol.
METHODS: A total of 17 glioblastoma patients were scanned at 3.0 T magnetic resonance imaging (MRI) every 6 weeks after tumor resection with standard MRI and T1 and T2 relaxometry before and after gadobutrol administration. On co-registered images T1w SI was measured and relaxation times T1 (qT1) and quantitative T2 (qT2) were quantified in several deep grey matter nuclei as ratios relative to frontal white matter and to the pons. Ratio changes were evaluated over time with a paired t‑test and multiple regression.
RESULTS: An average of 8 (range 5-14) scans per patient were completed. Ratios of T1w SI, qT1 and qT2 remained unchanged for all target regions from the first to the last time point (p > 0.05) and did not correlate with the number of gadobutrol administrations. Multivariate regression showed no significant impact of gadobutrol on qT1 or qT2 ratios, but a significant negative effect on T1w SI ratios. Gender also had no impact on the ratios but age had a significant negative influence on the qT1 ratio.
CONCLUSION: Multiple administrations of a macrocyclic contrast agent did not change relaxation time T1 ratios in any deep grey matter structure.

Entities:  

Keywords:  Cerebral gadolinium depositions; Dentate nucleus; Macrocyclic contrast agent; T1 relaxometry; T1-weighted signal intensity

Mesh:

Substances:

Year:  2017        PMID: 28741075     DOI: 10.1007/s00062-017-0608-6

Source DB:  PubMed          Journal:  Clin Neuroradiol        ISSN: 1869-1439            Impact factor:   3.649


  25 in total

1.  Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent.

Authors:  Alexander Radbruch; Lukas D Weberling; Pascal J Kieslich; Oliver Eidel; Sina Burth; Philipp Kickingereder; Sabine Heiland; Wolfgang Wick; Heinz-Peter Schlemmer; Martin Bendszus
Journal:  Radiology       Date:  2015-04-06       Impact factor: 11.105

2.  No Signal Intensity Increase in the Dentate Nucleus on Unenhanced T1-weighted MR Images after More than 20 Serial Injections of Macrocyclic Gadolinium-based Contrast Agents.

Authors:  Alexander Radbruch; Robert Haase; Pascal J Kieslich; Lukas D Weberling; Philipp Kickingereder; Wolfgang Wick; Heinz-Peter Schlemmer; Martin Bendszus
Journal:  Radiology       Date:  2016-12-07       Impact factor: 11.105

3.  Evaluation of brain ageing: a quantitative longitudinal MRI study over 7 years.

Authors:  René-Maxime Gracien; Lucas Nürnberger; Pavel Hok; Stephanie-Michelle Hof; Sarah C Reitz; Udo Rüb; Helmuth Steinmetz; Rüdiger Hilker-Roggendorf; Johannes C Klein; Ralf Deichmann; Simon Baudrexel
Journal:  Eur Radiol       Date:  2016-07-05       Impact factor: 5.315

4.  Pediatric Brain: No Increased Signal Intensity in the Dentate Nucleus on Unenhanced T1-weighted MR Images after Consecutive Exposure to a Macrocyclic Gadolinium-based Contrast Agent.

Authors:  Alexander Radbruch; Robert Haase; Philipp Kickingereder; Philipp Bäumer; Sebastian Bickelhaupt; Daniel Paech; Wolfgang Wick; Heinz-Peter Schlemmer; Angelika Seitz; Martin Bendszus
Journal:  Radiology       Date:  2017-03-08       Impact factor: 11.105

5.  Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy.

Authors:  Tomonori Kanda; Toshio Fukusato; Megumi Matsuda; Keiko Toyoda; Hiroshi Oba; Jun'ichi Kotoku; Takahiro Haruyama; Kazuhiro Kitajima; Shigeru Furui
Journal:  Radiology       Date:  2015-05-05       Impact factor: 11.105

6.  Macrocyclic and Other Non-Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function.

Authors:  Nozomu Murata; Luis F Gonzalez-Cuyar; Kiyoko Murata; Corinne Fligner; Russell Dills; Daniel Hippe; Kenneth R Maravilla
Journal:  Invest Radiol       Date:  2016-07       Impact factor: 6.016

Review 7.  Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update.

Authors:  J Ramalho; R C Semelka; M Ramalho; R H Nunes; M AlObaidy; M Castillo
Journal:  AJNR Am J Neuroradiol       Date:  2015-12-10       Impact factor: 3.825

8.  Nephrogenic systemic fibrosis: a serious iatrogenic disease of renal failure patients.

Authors:  Misbah Khurram; Lone Skov; Kristian Rossen; Henrik S Thomsen; Peter Marckmann
Journal:  Scand J Urol Nephrol       Date:  2007

9.  Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma.

Authors:  Andreas Müller; Alina Jurcoane; Sied Kebir; Philip Ditter; Felix Schrader; Ulrich Herrlinger; Theophilos Tzaridis; Burkhard Mädler; Hans H Schild; Martin Glas; Elke Hattingen
Journal:  Cancer Med       Date:  2016-11-28       Impact factor: 4.452

10.  Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease.

Authors:  Charles L Bennett; Zaina P Qureshi; A Oliver Sartor; Leann B Norris; Alanna Murday; Sudha Xirasagar; Henrik S Thomsen
Journal:  Clin Kidney J       Date:  2012-02
View more
  6 in total

1.  Prof. Dr. F. E. Zanella-A Training and Development Mentor in Neuroradiology.

Authors:  H Lanfermann; R D de Rochemont; J Berkefeld
Journal:  Clin Neuroradiol       Date:  2017-12       Impact factor: 3.649

Review 2.  Standardized assessment of the signal intensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium (GREC) Task Force position statement.

Authors:  Carlo C Quattrocchi; Joana Ramalho; Aart J van der Molen; Àlex Rovira; Alexander Radbruch
Journal:  Eur Radiol       Date:  2018-11-09       Impact factor: 5.315

3.  Gadolinium Retention in the Brain: An MRI Relaxometry Study of Linear and Macrocyclic Gadolinium-Based Contrast Agents in Multiple Sclerosis.

Authors:  Y Forslin; J Martola; Å Bergendal; S Fredrikson; M K Wiberg; T Granberg
Journal:  AJNR Am J Neuroradiol       Date:  2019-06-27       Impact factor: 3.825

4.  Absence of T1 Hyperintensity in the Brain of High-risk Patients After Multiple Administrations of High-dose Gadobutrol for Cardiac Magnetic Resonance.

Authors:  Antonella Meloni; Domenico Montanaro; Daniele De Marchi; Mariachiara Resta; Petra Keilberg; Laura Pistoia; Vincenzo Positano; Anna Spasiano; Tommaso Casini; Caterina Cinzia De Bari; Sara De Cori; Alessia Pepe
Journal:  Clin Neuroradiol       Date:  2020-03-17       Impact factor: 3.649

Review 5.  Gadobutrol in India-A Comprehensive Review of Safety and Efficacy.

Authors:  Jan Endrikat; Nicoletta Anzalone
Journal:  Magn Reson Insights       Date:  2017-09-11

6.  T1-weighted Grey Matter Signal Intensity Alterations After Multiple Administrations of Gadobutrol in Patients with Multiple Sclerosis, Referenced to White Matter.

Authors:  Peter Kelemen; Jamila Alaoui; Dominik Sieron; Andrew Chan; Christian P Kamm; Mirjam R Heldner; Jan Gralla; Roland Wiest; Rajeev K Verma
Journal:  Sci Rep       Date:  2018-11-15       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.